scholarly journals Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies

2018 ◽  
Vol 10 (7) ◽  
pp. 562-569 ◽  
Author(s):  
Won Sok Lee ◽  
Gurmukh Singh
Keyword(s):  
Light Chains ◽  
Free Light Chains ◽  
Serum Free ◽  
Monoclonal Gammopathies ◽  
Serum Free Light Chains ◽  
Kappa Light Chains

scholarly journals Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies

2015 ◽  
Vol 34 (1) ◽  
Author(s):  
Giovanni Cigliana ◽  
Eleonora Torti ◽  
Francesca Gulli ◽  
Elena De Santis ◽  
Maria Teresa Dell’Abate ◽  
...  
Keyword(s):  
Light Chains ◽  
Free Light Chains ◽  
Serum Free ◽  
Monoclonal Gammopathies ◽  
Serum Free Light Chains

scholarly journals Serum Free Light Chains: An Alternative to the Urine Bence Jones Proteins Screening Test for Monoclonal Gammopathies

2006 ◽  
Vol 52 (9) ◽  
pp. 1743-1748 ◽  
Author(s):  
Peter G Hill ◽  
Julia M Forsyth ◽  
Baldeep Rai ◽  
Stewart Mayne
Keyword(s):  
Light Chain ◽  
False Positive ◽  
False Positive Rate ◽  
Light Chains ◽  
Free Light Chains ◽  
Serum Free ◽  
Monoclonal Gammopathies ◽  
Positive Serum ◽  
Positive Rate ◽  
Serum Free Light Chains

Abstract Background: Retrospective analyses have established the role of quantitative serum free light chains (FLCs) in the diagnosis of monoclonal light chain disorders. The aims of this study were to assess (a) whether the addition of serum FLCs to serum protein electrophoresis (SPEP) identified additional patients with monoclonal gammopathies; (b) whether serum FLC measurements could replace urinalysis for Bence Jones protein (BJP); and (c) the cost/quality implications of routinely measuring serum FLCs. Methods: Serum FLCs were added to consecutive requests for SPEP from August to November 2004 and measured by automated immunoassay. Results: Seventy-one of 923 patients had abnormal serum FLC ratios. Seven patients with monoclonal gammopathies and 1 patient with malignant lymphoma (but no monoclonal band) were detected among 43 patients with negative SPEP but positive serum FLC ratios. Thirty-five patients with negative SPEP had false-positive serum FLC ratios. The false-positive rate for a ratio >1.65 was higher than previously described and associated with polyclonal increases in immunoglobulins and renal impairment. Serum FLC ratios were normal in 2 of 13 patients with low-level persistent urine BJP. However, no significant pathology would have been missed by replacing BJP with serum FLCs. Revenue and manpower savings offset 60% of the costs of serum FLCs. Conclusions: Additional diagnostic information is gained by adding serum FLCs to SPEP as first-line tests for investigating possible B-cell disorders. The quality of the diagnostic service is enhanced by more confident exclusion of light chain disorders and improved interpretive assessment of SPEP and immunofixation electrophoresis.

Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies

2020 ◽  
Vol 5 (6) ◽  
pp. 1358-1371
Author(s):  
Gurmukh Singh
Keyword(s):  
Light Chain ◽  
Protein Electrophoresis ◽  
Free Light Chain ◽  
Light Chains ◽  
Free Light Chains ◽  
Urine Protein ◽  
Serum Free ◽  
Monoclonal Gammopathies ◽  
Serum Free Light Chain ◽  
Serum Free Light Chains

Abstract Background Laboratory methods for diagnosis and monitoring of monoclonal gammopathies have evolved to include serum and urine protein electrophoresis, immunofixation electrophoresis, capillary zone electrophoresis, and immunosubtraction, serum-free light chain assay, mass spectrometry, and newly described QUIET. Content This review presents a critical appraisal of the test methods and reporting practices for the findings generated by the tests for monoclonal gammopathies. Recommendations for desirable practices to optimize test selection and provide value-added reports are presented. The shortcomings of the serum-free light chain assay are highlighted, and new assays for measuring monoclonal serum free light chains are addressed. Summary The various assays for screening, diagnosis, and monitoring of monoclonal gammopathies should be used in an algorithmic approach to avoid unnecessary testing. Reporting of the test results should be tailored to the clinical context of each individual patient to add value. Caution is urged in the interpretation of results of serum-free light chain assay, kappa/lambda ratio, and myeloma defining conditions. The distortions in serum-free light chain assay and development of oligoclonal bands in patients‘ status post hematopoietic stem cell transplants is emphasized and the need to note the location of original monoclonal Ig is stressed. The need for developing criteria that consider the differences in the biology of kappa and lambda light chain associated lesions is stressed. A new method of measuring monoclonal serum-free light chains is introduced. Reference is also made to a newly defined entity of light chain predominant intact immunoglobulin monoclonal gammopathy. The utility of urine testing in the diagnosis and monitoring of light chain only lesions is emphasized.

Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?

2007 ◽  
Vol 44 (6) ◽  
pp. 516-522 ◽  
Author(s):  
Robert Beetham ◽  
Julie Wassell ◽  
Michael J Wallage ◽  
Alastair J Whiteway ◽  
Jacky A James
Keyword(s):  
Light Chains ◽  
Free Light Chains ◽  
Serum Free ◽  
Monoclonal Gammopathies ◽  
Serum Free Light Chains
Sign in / Sign up

Export Citation Format

Share Document